Ensuring adhesion throughout the full usage period of a medicinal patch is a non-negotiable development requirement. Without effective adhesion, there is no intimate contact between the patch and skin, and without that contact, active ingredient absorption is compromised. In extended-wear patches — 3, 5, or 7-day systems — this challenge intensifies: skin perspires, patients shower, and the patch flexes and stretches with body movement.
When the patch’s primary formulation cannot achieve the adhesiveness required for the entire usage period on its own, the technical solution is to incorporate an adhesive overlay. This additional component, seemingly simple, presents its own formulation challenges that must be resolved with precision to avoid compromising either product safety or efficacy.
What Is an Adhesive Overlay and When Is It Incorporated?
The overlay is, in essence, an additional patch without active ingredient, larger than the medicinal patch, which covers it completely and ensures adherence through a greater skin contact surface.
It can be integrated into the product in two ways:
- As a separate component that the patient applies over the patch at the time of use.
- As an integral part of the device, incorporated during manufacturing as an additional layer in a multilayer system.
The design decision between both options depends on factors such as anticipated usage complexity, target patient profile, regulatory restrictions in the target market, and manufacturer capabilities.
The Three Critical Overlay Formulation Challenges
1. Compositional compatibility between overlay and active patch
The overlay’s composition may be similar to or different from that of the active patch, depending primarily on the adhesive capability sought. What is not optional is chemical compatibility between the two: overlay and patch are in intimate contact along the entire perimeter of the device.
An incorrect selection of overlay components can generate interactions with the active ingredient or with patch excipients, resulting in the formation of undesirable impurities in the product. This risk must be systematically evaluated during preformulation development, through compatibility studies covering the full spectrum of components in contact.
2. Overlay size: balancing adhesiveness and usability
The overlay is by definition larger than the active patch it covers. That size difference generates the additional skin contact surface and, with it, the additional adhesiveness that justifies its use.
But size also has functional limits. An overlay that is too large:
- Can make correct system application by the patient more difficult.
- Can generate discomfort during use, especially in high-mobility areas.
- Can increase the risk of peripheral detachment if the excess surface is not in firm contact with skin.
The final overlay size results from balancing the additional adhesiveness required against usability constraints. This balance must be validated clinically, not only in the laboratory.
3. Ability not to transport the active ingredient: the most critical challenge in high-potency drugs
This is the most technically demanding overlay characteristic and the one most frequently underestimated in early development stages.
Active ingredient absorption from the patch to skin depends on effective contact between both surfaces. If the active ingredient could diffuse from the patch edge into the overlay via concentration gradient, it would distribute across the entire overlay surface and could be absorbed through the skin over a much larger area than originally designed.
This alters the product’s defined release profile and, in high-potency medications, can generate overdosing with serious clinical consequences.
For this reason, overlays must not be interchanged between different medicinal patches, nor should household adhesive tapes be used to reinforce patch adhesion. Only the overlay designed and validated for that specific product guarantees predictable and safe behavior.
The overlay’s ability not to solubilize or transport the active ingredient must be evaluated through in vitro permeation studies and validated as part of the product’s technical package. It is not a parameter that can be assumed without experimental evidence.
Conclusion
The adhesive overlay is a valuable technical tool for solving adhesion problems in extended-wear medicinal patches, but its development is not trivial. Compositional compatibility, the balance between size and usability, and the ability to contain the active ingredient without transporting it are three challenges that must be addressed systematically and with solid experimental evidence.
A poorly formulated overlay can turn a technically well-designed product into one with safety or efficacy problems under real-use conditions.
